Skip to main content

Table 2 Geometric mean levels (GML) of pre- and post-vaccination antibody levels in patients with and without a history of serious infections after vaccination in all patients, and RA and SpA patients respectively

From: The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients

All patients No serious infections after vaccination Serious infections after vaccination
N = 470 N = 27
Antibody levels (mg/L) Antibody levels (mg/L)
GML; 95% CI GML; 95% CI
Serotype 6B
Pre-vaccination 1.8 (1.6-2.1) 1.1 (0.6-1.9)
Post-vaccination 4.1 (3.5-4.8) 2.2 (1.3-3.8)
Serotype 23 F
Pre-vaccination 0.8 (0.7-0.9) 0.4 (0.2-0.7)
Post-vaccination 2.6 (2.2-3.0) 1.5 (0.9-2.3)
RA patients No serious infections after vaccination Serious infections after vaccination
Serotype 6B
Pre-vaccination 1.7 (1.4-2.1) 1.0 (0.5-1.8)
Post-vaccination 3.1 (2.5-3.9) 2.0 ( 1.1-3.7)
Serotype 23 F
Pre-vaccination 0.7 (0.6-0.8) 0.3 (0.2-0.7)
Post-vaccination 1.8 (1.4-2.1) 1.4 (0.8-2.4)
SpA patients No serious infections after vaccination Serious infections after vaccination
Serotype 6B
Pre-vaccination 1.9 (1.6-2.4) 2.2 (0.5-9.8)
Post-vaccination 5.2 (4.1-6.5) 3.6 (0.7-17.4)
Serotype 23 F
Pre-vaccination 0.8 (0.7-1.0) 0.7 (0.2-2.3)
Post-vaccination 3.6 (3.0-4.5) 1.9 (0.5-6.9)
  1. CI, confidence interval; RA, rheumatoid arthritis; SpA, spondylarthropathy.